Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.

Scientific reports - 31 Jul 2024

Luo Dongdong, Luo Aiping, Hu Su, Ye Ganwei, Li Dan, Zhao Hailin, Peng Biao

Abstract excerpt

Glioblastoma (GBM) is a highly aggressive, infiltrative malignancy that cannot be completely cured by current treatment modalities, and therefore requires more precise molecular subtype signatures to predict treatment response for personalized precision therapy. Expression subtypes of GBM samples from the Cancer Genome Atlas (TCGA) were identified using BayesNM and compared with existing molecular subtypes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Gene Expression Regulation, Neoplastic

Share to Genomics

Share to Glioblastoma

Share to Immunotherapy

Share to Proteomics

Source

Open in PubMed Open full text

Identifiers

PMID: 39085480
DOI: 10.1038/s41598-024-68648-5
PMCID: PMC11292017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.PMID 39085480Read ↗

Molecular subtyping of glioblastoma based on immune-related genes for prognosisSemantic proximity Read ↗

A Novel MALT1-related Immune Prognostic Signature and Targeted Drug Screening for GlioblastomaSemantic proximity Read ↗

A Six-Immune-Related Genes Prognostic Signature for GlioblastomaSemantic proximity Read ↗

Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-SeqSemantic proximity Read ↗

Identification of an Immune-Related Prognostic Risk Model in GlioblastomaSemantic proximity Read ↗

Machine learning and multi-omics analysis reveal key regulators of proneural–mesenchymal transition in glioblastomaSemantic proximity Read ↗

Predictive Analyses of Prognostic-Related Immune Genes and Immune Infiltrates for GlioblastomaSemantic proximity Read ↗

Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy developmentSemantic proximity Read ↗

Construction and Validation of a Recurrence Prediction Model of Glioblastoma and Exploration of Its Biological FunctionsSemantic proximity Read ↗

Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for GlioblastomaSemantic proximity Read ↗

Establishment and validation of an immune-based prognostic score model in glioblastoma.Semantic proximity Read ↗

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.